Core Insights - Sight Sciences has appointed Alison Bauerlein as Chief Operating Officer and James Rodberg as Chief Financial Officer, effective November 5, 2025, to enhance its operational capabilities and drive growth in the interventional dry eye market [1][2] Leadership Appointments - The new appointments are aimed at strengthening the company's market leadership in minimally invasive glaucoma surgery (MIGS) and scaling the reimbursed interventional dry eye category [2] - Alison Bauerlein has a proven track record in leading high-growth medtech organizations and will focus on scaling the business [2][4] - James Rodberg brings a strong finance background and will support the company's growth and profitability goals [2][5] Board of Directors Update - Erica Rogers and Brenda Becker have stepped down from the Board of Directors, with acknowledgments of their contributions to the company's vision and mission [3] Company Overview - Sight Sciences is focused on developing innovative interventional solutions to improve patient care in eyecare, targeting prevalent eye diseases with minimally invasive approaches [7] - The company's products include the OMNI® Surgical System and TearCare® System, which address glaucoma and dry eye disease, respectively [7]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q3 2025 on November 6, 2025, with a conference call scheduled to discuss the results [1]. Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions aimed at transforming patient care and improving lives [3]. - The company utilizes minimally invasive or non-invasive methods to address prevalent eye diseases, aiming to enhance treatment paradigms and replace outdated approaches [3]. - Key products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are implant-free technologies for glaucoma surgery, and the TearCare® System, which is designed for treating evaporative dry eye disease [3]. Upcoming Events - The financial results for the third quarter ending September 30, 2025, will be reported after market close on November 6, 2025 [1]. - A conference call to discuss these results will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1]. - Investors can access a live and archived webcast of the conference call on the company's website [2].

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Virtual Ophthalmology Forum on May 27, 2025 [2] Company Overview - Sight Sciences specializes in minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The OMNI® Surgical System and OMNI® Edge Surgical System are implant-free technologies for glaucoma surgery, indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease, addressing the leading cause of dry eye [3]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, with a conference call scheduled to discuss the results [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions to improve patient care and address prevalent eye diseases [3] - The company's OMNI® Surgical System is designed for glaucoma surgery, indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical Instrument is a bladeless device used in ophthalmic procedures to excise trabecular meshwork [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]